Skip to main content

Table 4 Acute toxicities

From: A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer

 

Level 1 (n = 9)

Level 2 (n = 9)

Level 3 (n = 9)

G1

G2

G1

G2

G1

G2

RTOG

 GU

3

(33.3%)

3

(33.3%)

4

(44.4%)

1

(11.1%)

7

(77.8%)

0

(0.0%)

 GI

3

(33.3%)

0

(0.0%)

6

(66.7%)

0

(0.0%)

3

(33.3%)

1

(11.1%)

Micturition pain

1

(11.1%)

0

(0.0%)

3

(33.3%)

0

(0.0%)

1

(11.1%)

0

(0.0%)

Frequency

2

(22.2%)

3

(33.3%)

4

(44.4%)

1

(11.1%)

6

(66.7%)

0

(0.0%)

Urinary incontinence

1

(11.1%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Retention

1

(11.1%)

1

(11.1%)

2

(22.2%)

0

(0.0%)

1

(11.1%)

0

(0.0%)

Hematuria

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Stricture

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Proctitis

2

(22.2%)

0

(0.0%)

3

(33.3%)

0

(0.0%)

3

(33.3%)

0

(0.0%)

Fecal incontinence

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Diarrhea

1

(11.1%)

0

(0.0%)

3

(33.3%)

0

(0.0%)

0

(0.0%)

0

(0.0%)

Rectal hemorrhage

1

(11.1%)

0

(0.0%)

4

(44.4%)

0

(0.0%)

1

(11.1%)

1

(11.1%)

  1. GU Genitourinary toxicity, GI Gastrointestinal toxicity, RTOG Radiation therapy oncology group